Predicting the duration of antiviral treatment needed to suppress plasma HIV-1 RNA

Journal of Clinical Investigation

Volumn 105, Issue 6, 2000, Pages 777-782

  Rizzardi, G Paolo ^a   De Boer, Rob J ^b   Hoover, Shelley ^c   Tambussi, Giuseppe ^d   Chapuis, Aude ^a   Halkic, Nermin ^e   Bart, Pierre Alexandre ^a   Miller, Veronica ^f   Staszewski, Schlomo ^f   Notermans, Daan W ^g   Perrin, Luc ^h   Fox, Cecil H ^c   Lange, Joep M A ^g   Lazzarin, Adriano ^d   Pantaleo, Giuseppe ^a,e  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b UTRECHT UNIVERSITY   (Netherlands)

^c Molecular Histology Labs   (United States)

^d SAN RAFFAELE HOSPITAL   (Italy)

^e LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^f UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^g UNIVERSITY OF AMSTERDAM   (Netherlands)

^h GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; NELFINAVIR; RITONAVIR; SAQUINAVIR; STAVUDINE; VIRUS RNA; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; HELPER CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; VIREMIA; VIRUS LOAD;

EID: 0034105302     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI9079     Document Type: Article

References (33)

1. Deeks, S.G., Smith, M., Holodniy, M., and Kahn, J.O. 1997. HIV-1 protease inhibitors. A review for clinicians. JAMA. 277:145-153.
2. Gulick, R.M., et al. 1997. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N. Engl. J. Med. 337:734-739.
3. Hammer, S.M., et al. 1997. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N. Engl. J. Med. 337:725-733.
4. Flexner, C. 1998. HIV-protease inhibitors. N. Engl. J. Med. 338:1281-1292.
5. Hammer, S.M., and Yeni, P. 1998. Antiretroviral therapy: where are we? AIDS. 12(Suppl. A):S181-S188.
6. Kempf, D.J., et al. 1998. The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir. AIDS. 12:F9-14.
7. Raboud, J.M., et al. 1998. Suppression of plasma viral load below 20 copies/ml is required to achieve a long-term response to therapy. AIDS. 12:1619-1624.
8. Katzenstein, D.A., et al. 1996. The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team [erratum 1997, 15:1097]. N. Engl. J. Med. 335:1091-1098.
9. O'Brien, W.A., et al. 1996. Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS. N. Engl. J. Med. 334:426-431.
10. Delta Coordinating Committee and Delta Virology Committee. 1999. HIV-1 RNA response to antiretroviral treatment in 1280 participants in the Delta Trial: an extended virology study AIDS. 13:57-65.
11. Montaner, J.S., Hogg, R., Raboud, J., Harrigan, R., and O'Shaughnessy, M. 1998. Antiretroviral treatment in 1998. Lancet. 352:1919-1922.
12. Rizzardi, G.P., et al. 1999. Quantitative normalization of CD4+ T cells in blood and lymph nodes of HIV-1-infected therapy-naive adults at early stage of chronic infection treated with abacavir plus amprenavir. Interscience Conference on Antimicrobial Agents and Chemotherapy, 39th, San Francisco. 508: 1822. (Abstr.)
13. Rizzardi, G.R., et al. 1999. Effect of HAART and immune-based strategies in HIV-1-infected antiretroviral naive adults. Interscience Conference on Antimicrobial Agents and Chemotherapy, 39th, San Francisco. 488:691. (Abstr.)
14. Reijers, M.H., et al. 1998. Maintenance therapy after quadruple induction therapy in HIV-1 infected individuals: Amsterdam Duration of Antiretroviral Medication (ADAM) study. Lancet. 352:185-190.
15. Notermans, D.W., et al. 1998. Decrease of HIV-1 RNA levels in lymphoid tissue and peripheral blood during treatment with ritonavir, lamivudine and zidovudine. Ritonavir/3TC/ZDV Study Group. AIDS. 12:167-173.
16. Staszewski, S., et al. 1999. Comparison of antiviral response with abacavir/combivir to indinavir/combivir in therapy-naive adults at 48 weeks (CNA3005). Interscience Conference on Antimicrobial Agents and Chemotherapy, 39th, San Francisco. 472:505. (Abstr.)
17. Pantaleo, G., et al. 1998. Evolutionary pattern of human immunodeficiency virus (HIV) replication and distribution in lymph nodes following primary infection: implications for antiviral therapy. Nat. Med. 4:341-345.
18. Embretson, J., et al. 1993. Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS. Nature. 362:359-362.
19. Emilie, D., et al. 1990. Production of interleukins in human immunodeficiency virus-1-replicating lymph nodes. J. Clin. Invest. 86:148-159.
20. Fox, C.H., et al. 1991. Lymphoid germinal centers are reservoirs of human immunodeficiency virus type I RNA [erratum 1992,6:1161]. J. Infect. Dis. 164:1051-1057.
21. Pantaleo, G., et al. 1991. Lymphoid organs function as major reservoirs for human immunodeficiency virus. Proc. Natl. Acad Sci. USA. 88:9838-9842.
22. Pantaleo, G., et al. 1993. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature. 362:355-358.
23. Spiegel, H., Herbst, H., Niedobitek, G., Foss, H.D., and Stein, H. 1992. Follicular dendritic cells are a major reservoir for human immunodeficiency virus type 1 in lymphoid tissues facilitating infection of CD4+ T-helper cells. Am. J. Pathol. 140:15-22.
24. Tenner-Racz, K., Racz, P., Dietrich, M., and Kern, P. 1985. Altered follicular dendritic cells and virus-like particles in AIDS and AIDS-related lymphadenopathy. Lancet. 1:105-106.
25. Fox, C.H., and Cottler-Fox, M. 1993. In situ hybridization for the detection of HIV RNA in cells and tissues. In Current protocols in immunology. J. Coligan, A. Kruisbeek, D. Margulies, E. Shevach, and W. Strober, editors. John Wiley & Sons. New York, NY.
26. Cottler-Fox, M. and Fox, C.H. 1991. Examining cells for infectious agents: a novel approach. J. Infect. Dis. 164:1239-1240.
27. Fox, C.H., Hoover, S., Currall, V.R., Bahre, H.J., and Cottler-Fox, M. 1994. HIV in infected lymph nodes. Nature. 370:256.
28. Haase, A.T., et al. 1996. Quantitative image analysis of HIV-1 infection in lymphoid tissue. Science. 274:985-989.
29. Cavert, W., et al. 1997. Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection. Science. 276:960-964.
30. Mellors, J.W., et al. 1996. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma [erratum 1997, 5296:14]. Science. 272:1167-1170.
31. Mellors, J.W., et al. 1997. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann. Intern. Med. 126:946-954.
32. Perelson, A.S., Neumann, A.U., Markowitz, M., Leonard, J.M., and Ho, D.D. 1996. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science. 271:1582-1586.
33. Perelson, A.S., et al. 1997. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature. 387:188-191.